Valeo Pharma Stock Total Asset

VPHIF Stock  USD 0.05  0.00  0.00%   
Valeo Pharma fundamentals help investors to digest information that contributes to Valeo Pharma's financial success or failures. It also enables traders to predict the movement of Valeo Pink Sheet. The fundamental analysis module provides a way to measure Valeo Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Valeo Pharma pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Valeo Pharma Company Total Asset Analysis

Valeo Pharma's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

 = 

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current Valeo Pharma Total Asset

    
  58.27 M  
Most of Valeo Pharma's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Valeo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition

Based on the latest financial disclosure, Valeo Pharma has a Total Asset of 58.27 M. This is 99.23% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The total asset for all United States stocks is 99.8% higher than that of the company.

Valeo Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Valeo Pharma's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Valeo Pharma could also be used in its relative valuation, which is a method of valuing Valeo Pharma by comparing valuation metrics of similar companies.
Valeo Pharma is currently under evaluation in total asset category among its peers.

Valeo Fundamentals

About Valeo Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Valeo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Valeo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Valeo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Valeo Pink Sheet

Valeo Pharma financial ratios help investors to determine whether Valeo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Valeo with respect to the benefits of owning Valeo Pharma security.